Small Molecule, TLR-4 Ligands as Immunomodulators
- Technology Benefits
- • Small molecules are more readily scaled and controlled in drug development (vs. proteins and peptides)• TLR-4 specificity allows one to modulate the immune response in a more cell-specific manner• Small molecules easily modified to enable linking to other TLR-agonists for combined drugs
- Technology Application
- Compositions may be useful for the treatment of cancer and infectious diseases. Tolerance inducers may be useful for inflammatory and autoimmune disorders, including but not limited to as toxic shock, multiple sclerosis or diabetes. Those that are not inflammatory of cytokines appear to be useful for inducing tolerant.
- Detailed Technology Description
- UC researchers have validated means of using TLR-4-specific small molecules as immunomodulatory compositions. Strong ligands are useful as vaccine adjuvants, anticancer agents and immune-stimulants; more weakly binding compositions have been substantially validated, in vivo, for inducing tolerance.
- Application No.
- 9505768
- Others
-
State Of Development
Inventors have confirmed the molecular target in mouse and human models and have generated structure-activity relationships around hits. For some compositions, activity has been confirmed in vivo. Tolerance induction has been tested in nine distinct murine models of autoimmunity and/or inflammation. Additional animal studies and lead optimization are in process.
Other Information
Dev, A., et al., (2011), NF-κB and innate immunity, Curr. Top. Microbiol. Immunol., 349, 115-143.
Intellectual Property Info
Worldwide rights available; Pending patents available under confidentiality.
Related Materials
Pu, M., et al., (2012) Analysis of high-throughput screening assays using cluster enrichment, Stat Med,1191-1195.
Fang, H. et al., (2011), Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response, J. Biol. Chem., 286, 30393-30400.
Coffman, R. L. et. al., (2010) Vaccine adjuvants: putting innate immunity to work, Immunity, 33, 492-503.
Wu CC, et al., Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand. J Innate Immun. 2014;6(3):315-24.
Nour A, et al., Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands. Bioorg Med Chem Lett. 2014 Nov 1;24(21):4931-8.
Goff PH, et al., Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses. J Virol. 2015 Mar 15;89(6):3221-35. doi: 10.1128/JVI.03337-14. Epub 2015 Jan 7.Tech ID/UC Case
23140/2013-065-0
Related Cases
2013-065-0, 2014-123-0
- *Abstract
-
As part of a comprehensive campaign to screen for effective vaccine adjuvants, 180,000 compounds were tested in a cell-based HTS screen to assess ability to activate NF-kB. Several classes of scaffolds bearing appropriate substitutions were found to stimulate innate immune responses and some of these scaffolds were structurally different from all other known ligands. More interestingly, the structure of one class of scaffolds challenges current dogma regarding what is necessary for efficacy.
- *IP Issue Date
- Nov 29, 2016
- *Principal Investigator
-
Name: Dennis Carson
Department:
Name: Michael Chan
Department:
Name: Mary Corr
Department:
Name: Howard Cottam
Department:
Name: Tomoko Hayashi
Department:
- Country/Region
- USA
